The US Federal Trade Commission has ruled Impax Laboratories entered into an illegal $112mn “pay-for-delay” settlement to block consumers’ access to a cheaper version of Endo Pharmaceuticals’ branded extended-release opioid pain reliever Opana ER.
FTC Rules Impax $112mn Pay-For-Delay Deal With Endo Was Illegal
Agreeing a deal that it would not face an authorized generic during its 180-day market exclusivity for generic Opana ER contributed to Amneal's Impax striking an illegal pay-for-delay settlement, the FTC is alleging
